MiMedx Group Inc (MDXG) was Reiterated by Needham to “Strong Buy” while Lowering the Price Target of the company shares to $ 12 from a previous price target of $13 . Needham advised their investors in a research report released on Apr 12, 2016.
Many Wall Street Analysts have commented on MiMedx Group Inc. Shares were Reiterated by Needham on Apr 12, 2016 to “Strong Buy” and Lowered the Price Target to $ 12 from a previous price target of $13 .Shares were Reiterated by Needham on Apr 11, 2016 to “Strong Buy” and Lowered the Price Target to $ 12 from a previous price target of $13 .Company shares were Reiterated by First Analysis Sec on Jan 20, 2016 to “Overweight”, Firm has raised the Price Target to $ 15 from a previous price target of $11 .
On the company’s financial health, MiMedx Group Inc reported $0.07 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Feb 23, 2016. Analyst had a consensus of $0.06. The company had revenue of $51.80 million for the quarter, compared to analysts expectations of $51.53 million. The company’s revenue was up 30.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.03 EPS.
MiMedx Group Inc closed down -0.79 points or -8.79% at $8.2 with 38,57,932 shares getting traded on Monday. Post opening the session at $7.66, the shares hit an intraday low of $7.46 and an intraday high of $8.32 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Nov 16, 2015, Charles Robert Evans (director) purchased 10,000 shares at $7.84 per share price. According to the SEC, on Nov 10, 2015, Parker H Petit (CEO) purchased 131,925 shares at $7.58 per share price. On Oct 30, 2015, Alexandra O Haden (General Counsel & Secretary) purchased 4,150 shares at $7.92 per share price, according to the Form-4 filing with the securities and exchange commission.
MiMedx Group Inc. (MiMedx) is an integrated developer manufacturer and marketer of regenerative biomaterial products and bioimplants processed from human amniotic membrane. The Company’s biomaterial platform technologies include AmnioFix and EpiFix its tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through its donor program mothers delivering full-term Cesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. MiMedx processes the human amniotic membrane utilizing its Purion Process to produce an implant which is referred as an allograft. MiMedx is the supplier of amniotic tissue having supplied over 350000 allografts for application in the Wound Care Surgical Sports Medicine Ophthalmic and Dental sectors of healthcare. Its CollaFix technology combines a means of creating fibers from soluble collagen and a cross-linking process.